Although previous studies have observed that Black patients are less likely to receive kidney transplants than White patients, the points of inequity in the transplant process were unclear.
In the BETonMACE trial, CKD patients with type 2 diabetes who recently experienced acute coronary syndrome who received apabetalone had a significant 50% reduction in the risk for major cardiovascular events compared with placebo.
Difelikefalin, an investigational intravenous drug, improved moderate to severe itching compared with placebo in patients on hemodialysis, according to phase 3 trial results.
Finerenone vs placebo added to standard therapy was associated with a significant 18% reduction in the risk for major adverse kidney events in patients with both chronic kidney disease and type 2 diabetes mellitus.
COVID-19 is associated with higher hospitalization and death rates among patients with end-stage kidney disease on a kidney transplant waitlist compared with kidney transplant recipients.
Early data from a small ongoing trial shows that pegloticase, which is administered by injection, can result in substantial and sustained decreases in serum uric acid in kidney transplant recipients with treatment-refractory gout.
Patients with influenza who developed acute kidney injury, compared with those who did not, had 3.8-fold higher odds for death, investigators reported.
Dietary modification to reduce the risk of hyperkalemia in patients undergoing maintenance hemodialysis is standard practice and is commonly recommended in guidelines despite a lack of evidence.
